Melanie J Marota

US Patent:

20190209478, Jul 11, 2019

Filed:

Nov 2, 2018

Appl. No.:

16/178641

Inventors:

- Rahway NJ, US
Leonardo Resende Allain - Lansdale PA, US
W. Mark Eickhoff - Lansdale PA, US
Craig B. Ikeda - Harleysville PA, US
Chad D. Brown - Quakertown PA, US
Rebecca Nofsinger - Lansdale PA, US
Melanie Marota - Lansdale PA, US
Lisa Lupton - South San Francisco CA, US
Paresh B. Patel - Langhorne PA, US
Hanmi Xi - Furlong PA, US
Wei Xu - North Wales PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 9/20
A61K 31/4545
A61K 31/437

Abstract:

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API):wherein “R” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.

US Patent:

20180228828, Aug 16, 2018

Filed:

Jul 29, 2016

Appl. No.:

15/750064

Inventors:

- RAHWAY NJ, US
William A Marinaro - Scotch Plains NJ, US
Jesse Lee Kuiper - North Wales PA, US
Craig Alfred McKelvey - Ambler PA, US
Melanie J. Marota - Lansdale PA, US

Assignee:

MERCK SHARP & DOHME CORP. - RAHWAY NJ

International Classification:

A61K 31/7072
A61K 31/5365
A61K 31/498
A61K 9/14
A61K 9/16
A61K 9/20

Abstract:

The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor; a first solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof, and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof, and optionally one or more excipients, and a second solid dispersion formulation, which comprises an HCV NS3 inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof, and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof, and optionally one or more excipients. The present disclosure is also directed to oral dosage forms, such as tablets or capsules comprising the disclosed blended compositions comprising the disclosed solid dispersion formulations, and the methods for making these solid dispersion formulations, and pharmaceutical compositions.

US Patent:

20160346214, Dec 1, 2016

Filed:

Jan 30, 2015

Appl. No.:

15/115026

Inventors:

- Rahway NJ, US
Leonardo Resende Allain - Lansdale PA, US
W. Mark Eickhoff - Lansdale PA, US
Craig B. Ikeda - Harleysville PA, US
Chad D. Brown - Quakertown PA, US
Rebecca Nofsinger - Lansdale PA, US
Melanie Marota - Lansdale PA, US
Lisa Lupton - South San Francisco CA, US
Paresh B. Patel - Langhorne PA, US
Hanmi Xi - Furlong PA, US
Wei Xu - North Wales PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 9/20
A61K 31/4545

Abstract:

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein “R” is independently H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.